Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,962 | 7,195 | 15,193 | -62,293 | -50,180 |
| Depreciation Amortization | -1,005 | -574 | -269 | -1,056 | -834 |
| Accounts receivable | 43 | -11 | -4 | -49 | -44 |
| Accounts payable and accrued liabilities | -608 | 555 | -1,274 | 1,057 | 348 |
| Other Working Capital | 2,495 | 3,045 | 152 | -1,647 | -188 |
| Other Operating Activity | -21,569 | -24,250 | -22,061 | 38,564 | 33,939 |
| Operating Cash Flow | $-23,606 | $-14,040 | $-8,263 | $-25,424 | $-16,959 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -18,527 | -15,909 | 4,279 | -27,489 | -21,401 |
| PPE Investments | -149 | -149 | -36 | 5 | N/A |
| Investing Cash Flow | $-18,676 | $-16,058 | $4,243 | $-27,484 | $-21,401 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 36,409 | 36,049 | 279 | 49,028 | 30,420 |
| Financing Cash Flow | $36,409 | $36,049 | $279 | $49,028 | $30,420 |
| Beginning Cash Position | 8,740 | 8,740 | 8,740 | 12,620 | 12,620 |
| End Cash Position | 2,867 | 14,691 | 4,999 | 8,740 | 4,680 |
| Net Cash Flow | $-5,873 | $5,951 | $-3,741 | $-3,880 | $-7,940 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,606 | -14,040 | -8,263 | -25,424 | -16,959 |
| Capital Expenditure | -149 | -149 | -36 | N/A | N/A |
| Free Cash Flow | -23,755 | -14,189 | -8,299 | -25,424 | -16,959 |